BIOMAT Database Logo BIOMAT Database Logo

Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. 2003

R W Gelling, and X Q Du, and D S Dichmann, and J Romer, and H Huang, and L Cui, and S Obici, and B Tang, and J J Holst, and C Fledelius, and P B Johansen, and L Rossetti, and L A Jelicks, and P Serup, and E Nishimura, and M J Charron
Department of Diabetes Biology, Pharmacological Research 2, Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark.

Glucagon, the counter-regulatory hormone to insulin, is secreted from pancreatic alpha cells in response to low blood glucose. To examine the role of glucagon in glucose homeostasis, mice were generated with a null mutation of the glucagon receptor (Gcgr(-/-)). These mice display lower blood glucose levels throughout the day and improved glucose tolerance but similar insulin levels compared with control animals. Gcgr(-/-) mice displayed supraphysiological glucagon levels associated with postnatal enlargement of the pancreas and hyperplasia of islets due predominantly to alpha cell, and to a lesser extent, delta cell proliferation. In addition, increased proglucagon expression and processing resulted in increased pancreatic glucogen-like peptide 1 (GLP-1) (1-37) and GLP-1 amide (1-36 amide) content and a 3- to 10-fold increase in circulating GLP-1 amide. Gcgr(-/-) mice also displayed reduced adiposity and leptin levels but normal body weight, food intake, and energy expenditure. These data indicate that glucagon is essential for maintenance of normal glycemia and postnatal regulation of islet and alpha and delta cell numbers. Furthermore, the lean phenotype of Gcgr(-/-) mice suggests glucagon action may be involved in the regulation of whole body composition.

UI MeSH Term Description Entries
D006965 Hyperplasia An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells. Hyperplasias
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007515 Islets of Langerhans Irregular microscopic structures consisting of cords of endocrine cells that are scattered throughout the PANCREAS among the exocrine acini. Each islet is surrounded by connective tissue fibers and penetrated by a network of capillaries. There are four major cell types. The most abundant beta cells (50-80%) secrete INSULIN. Alpha cells (5-20%) secrete GLUCAGON. PP cells (10-35%) secrete PANCREATIC POLYPEPTIDE. Delta cells (~5%) secrete SOMATOSTATIN. Islands of Langerhans,Islet Cells,Nesidioblasts,Pancreas, Endocrine,Pancreatic Islets,Cell, Islet,Cells, Islet,Endocrine Pancreas,Islet Cell,Islet, Pancreatic,Islets, Pancreatic,Langerhans Islands,Langerhans Islets,Nesidioblast,Pancreatic Islet
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D008856 Microscopy, Fluorescence Microscopy of specimens stained with fluorescent dye (usually fluorescein isothiocyanate) or of naturally fluorescent materials, which emit light when exposed to ultraviolet or blue light. Immunofluorescence microscopy utilizes antibodies that are labeled with fluorescent dye. Fluorescence Microscopy,Immunofluorescence Microscopy,Microscopy, Immunofluorescence,Fluorescence Microscopies,Immunofluorescence Microscopies,Microscopies, Fluorescence,Microscopies, Immunofluorescence
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D001786 Blood Glucose Glucose in blood. Blood Sugar,Glucose, Blood,Sugar, Blood

Related Publications

R W Gelling, and X Q Du, and D S Dichmann, and J Romer, and H Huang, and L Cui, and S Obici, and B Tang, and J J Holst, and C Fledelius, and P B Johansen, and L Rossetti, and L A Jelicks, and P Serup, and E Nishimura, and M J Charron
Pancreatic α-cell hyperplasia and hyperglucagonemia due to a glucagon receptor splice mutation.
January 2016, Endocrinology, diabetes & metabolism case reports,
R W Gelling, and X Q Du, and D S Dichmann, and J Romer, and H Huang, and L Cui, and S Obici, and B Tang, and J J Holst, and C Fledelius, and P B Johansen, and L Rossetti, and L A Jelicks, and P Serup, and E Nishimura, and M J Charron
Crispr-Cas9 mediated complete deletion of glucagon receptor in mice display hyperglucagonemia and α-cell hyperplasia.
February 2023, Biochemical and biophysical research communications,
R W Gelling, and X Q Du, and D S Dichmann, and J Romer, and H Huang, and L Cui, and S Obici, and B Tang, and J J Holst, and C Fledelius, and P B Johansen, and L Rossetti, and L A Jelicks, and P Serup, and E Nishimura, and M J Charron
Exocrine pancreas hyperplasia without dysplasia in glucagon receptor knockout mice.
January 2014, Pancreas,
R W Gelling, and X Q Du, and D S Dichmann, and J Romer, and H Huang, and L Cui, and S Obici, and B Tang, and J J Holst, and C Fledelius, and P B Johansen, and L Rossetti, and L A Jelicks, and P Serup, and E Nishimura, and M J Charron
Homozygous P86S mutation of the human glucagon receptor is associated with hyperglucagonemia, alpha cell hyperplasia, and islet cell tumor.
November 2009, Pancreas,
R W Gelling, and X Q Du, and D S Dichmann, and J Romer, and H Huang, and L Cui, and S Obici, and B Tang, and J J Holst, and C Fledelius, and P B Johansen, and L Rossetti, and L A Jelicks, and P Serup, and E Nishimura, and M J Charron
Angptl4 does not control hyperglucagonemia or α-cell hyperplasia following glucagon receptor inhibition.
March 2017, Proceedings of the National Academy of Sciences of the United States of America,
R W Gelling, and X Q Du, and D S Dichmann, and J Romer, and H Huang, and L Cui, and S Obici, and B Tang, and J J Holst, and C Fledelius, and P B Johansen, and L Rossetti, and L A Jelicks, and P Serup, and E Nishimura, and M J Charron
Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia.
December 2009, The Journal of pharmacology and experimental therapeutics,
R W Gelling, and X Q Du, and D S Dichmann, and J Romer, and H Huang, and L Cui, and S Obici, and B Tang, and J J Holst, and C Fledelius, and P B Johansen, and L Rossetti, and L A Jelicks, and P Serup, and E Nishimura, and M J Charron
The glucagon receptor antagonist desHis1Pro4Glu9-glucagon(Lys12PAL) alters alpha-cell turnover and lineage in mice, but does not cause alpha-cell hyperplasia.
June 2023, Molecular and cellular endocrinology,
R W Gelling, and X Q Du, and D S Dichmann, and J Romer, and H Huang, and L Cui, and S Obici, and B Tang, and J J Holst, and C Fledelius, and P B Johansen, and L Rossetti, and L A Jelicks, and P Serup, and E Nishimura, and M J Charron
Glucagon replacement via micro-osmotic pump corrects hypoglycemia and alpha-cell hyperplasia in prohormone convertase 2 knockout mice.
February 2002, Diabetes,
R W Gelling, and X Q Du, and D S Dichmann, and J Romer, and H Huang, and L Cui, and S Obici, and B Tang, and J J Holst, and C Fledelius, and P B Johansen, and L Rossetti, and L A Jelicks, and P Serup, and E Nishimura, and M J Charron
Amino Acid Transporter Slc38a5 Controls Glucagon Receptor Inhibition-Induced Pancreatic α Cell Hyperplasia in Mice.
June 2017, Cell metabolism,
R W Gelling, and X Q Du, and D S Dichmann, and J Romer, and H Huang, and L Cui, and S Obici, and B Tang, and J J Holst, and C Fledelius, and P B Johansen, and L Rossetti, and L A Jelicks, and P Serup, and E Nishimura, and M J Charron
Pathways of Glucagon Secretion and Trafficking in the Pancreatic Alpha Cell: Novel Pathways, Proteins, and Targets for Hyperglucagonemia.
January 2021, Frontiers in endocrinology,
Copied contents to your clipboard!